Zhejiang East Asia Pharmaceutical Co Ltd. Stock Analysis 605177.SS

Zhejiang East Asia Pharmaceutical Co., Ltd. engages in the manufacture and distribution of active pharmaceutical ingredients (API), tablets, granules and capsules. The company is headquartered in Taizhou, Zhejiang and currently employs 1,514 full-time employees. The company went IPO on 2020-11-25. The firm's products mainly cover antibacterial drugs (including β-lactams and quinolones), anticholinergic and synthetic antispasmodic drugs (including trimebutine maleate) and antifungal drugs for skin. The firm's anticholinergic and synthetic antispasmodics are mainly used to treat gastrointestinal smooth muscle spasm and functional gastrointestinal diseases. The firm distributes its products in domestic market and to overseas markets.